股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: 2025年8月31日 | | --- | | 狀態: | | 新提交 | 致：香港交易及結算所有限公司 公司名稱: 醫脈通科技有限公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02192 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 50,000,000,000 | USD | | 0.00001 | USD | | 500,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 50,000,000,000 | USD | | 0.00001 | USD ...

| 股份代號: | 02192 | | --- | --- | | 上市法國名稱: | 醫脈通科技有限公司 | | 日期 (日 / 月 / 年): | 01/08/2025 - 01/09/2025 | 增持后，富国基金管理有限公司最新持股数目为3734.65万股，持股比例由4.86%上升至5.09%。 | 張格序號 | 大股東/董事/最高行政人員名 作出披露的 買入 / 賣出或涉及的 每股的平均價 | | | | 持有權益的股份數目 佔已發行的 有關事件的日期相關 | | --- | --- | --- | --- | --- | --- | | | | 原因 | 股份數目 | | (請參閱上述 * 註 有投票權股 (日 / 月 / 年) 權 | | | | | | | 份百分比 | | | | | | | (%) | | CS20250829E00024 | 富国基金管理有限公司 | 1001(L) | 1,671,500(L | HKD 14.5086 | 37,346,500(L) 5.09(L)27/08/2025 | 格隆汇9月1日丨根据联交所最新权益披露资料显示，2025年8月27日，医脉通(0 ...

Group 1 - The core point of the article is that Franklin Templeton has increased its stake in the company Medlinker (02192) by acquiring 1.6715 million shares at a price of HKD 14.5086 per share, totaling approximately HKD 24.2511 million [1] - After the acquisition, Franklin Templeton's total shareholding in Medlinker is now 37.3465 million shares, representing a 5.09% ownership stake [1]

智通财经APP获悉，香港联交所最新数据显示，8月27日，富国基金增持医脉通(02192)167.15万股，每 股作价14.5086港元，总金额约为2425.11万港元。增持后最新持股数目为3734.65万股，持股比例为 5.09%。 ...

Core Insights - The company reported better-than-expected performance for 1H25, with revenue of 312 million yuan (+28.2% YoY) and net profit attributable to shareholders of 166 million yuan (+4.3% YoY) [1][2] - The growth in revenue is attributed to a rapid increase in the number of collaborative projects [1] Financial Performance - Non-IFRS EBIT for 1H25 reached 72.69 million yuan (+36.4% YoY), with a corresponding profit margin of 23.3% (+1.4 percentage points YoY) [1][2] - The gross margin for 1H25 was reported at 59.0% (-1.6 percentage points YoY), influenced by increased costs associated with digital marketing projects for pharmaceutical clients [2] Revenue Breakdown - Revenue by business segment for 1H25: Precision Marketing and Enterprise Solutions at 292 million yuan (+29.6% YoY), Medical Knowledge Solutions at 9.195 million yuan (+9.2% YoY), and Intelligent Patient Management Solutions at 10.46 million yuan (+11.5% YoY) [1] - Revenue by region for 1H25: Domestic revenue at 304 million yuan (+28.0% YoY) and overseas revenue at 77.55 million yuan (+37.5% YoY) [1] Client Engagement - The number of clients covered by Precision Education and Enterprise Solutions increased to 191 (+20.9% YoY), with a total of 445 projects (+32.4% YoY) [1] - The average number of collaborative projects per enterprise increased to approximately 2.3 in 1H25, compared to 2.1 in 1H24 [1] Dividend Policy - The company plans to distribute a dividend of 0.1166 yuan per share, with a total dividend payout of 85.615 million yuan, representing a payout ratio of approximately 55% [2] Product Development - The company launched AI products such as MedSeeker, MedPaper, and MedAssister, aimed at assisting physicians in clinical decision-making and improving research efficiency [3] - A new content generation module for pharmaceutical clients was introduced, which can reduce labor costs by 50% while ensuring content professionalism and compliance [3] Valuation and Forecast - The company maintains its target price at 17.5 HKD, based on a 39x EV/EBIT valuation for 2025, with a current trading multiple of approximately 28x [3]

研究报告 Research Report 28 Aug 2025 医脉通 Medlive Technology (2192 HK) 25H1 业绩符合预期，应用 AI 技术提升平台能力 Performance meets expectations, applying AI technology to enhance platform capabilities [Table_yemei 观点聚焦 1] Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$14.07 目标价 HK$15.00 HTI ESG 5.0-5.0-5.0 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$10.33bn / US$1.33bn 日交易额 (3 个月均值) US$6.90mn 发行股票数目 734.26mn 自由流通股 (%) 26% 1 年股价最高最低值 HK$17.04-HK$7.20 注：现价 HK$14.07 为 2025 ...

Core Viewpoint - The stock of Yimaitong (02192) experienced a decline of over 5% during trading, currently down 4.3% at HKD 14.02, with a trading volume of HKD 32.4476 million [1] Financial Performance - For the six months ending June 30, 2025, Yimaitong reported revenue of RMB 312 million, representing a year-on-year increase of 28.2% [1] - The profit attributable to the owners of the parent company was RMB 155 million, reflecting a year-on-year increase of 5.9% [1] - Basic earnings per share were reported at 21.2 cents [1] Dividend Announcement - The board of directors declared an interim dividend of RMB 11.66 cents per ordinary share, compared to RMB 12.05 cents in the same period last year [1]

消息面上，医脉通发布截至2025年6月30日止6个月业绩，该集团期内取得收益3.12亿元人民币，同比增 加28.2%；母公司拥有人应占溢利1.55亿元，同比增加5.9%；每股基本盈利21.2分。此外，董事会决议 宣布派发中期股息每股普通股人民币11.66分，去年同期为人民币12.05分。 智通财经APP获悉，医脉通(02192)盘中跌超5%，截至发稿，跌4.3%，报14.02港元，成交额3244.76万港 元。 ...

88%执业医师的伙伴，精准营销助力创新药商业化，AI 持续赋能平台 [Table_CoverStock] —医脉通(2192.HK)公司深度报告 [Table_ReportDate] 2025 年 8 月 25 日 S1500523080002 S1500524030003 [Table_CoverAuthor] 唐爱金 医药行业首席分析师 章钟涛 医药行业分析师 tangaijin@cindasc.com zhangzhongtao@cindasc.com 证券研究报告 公司研究 [Table_ReportType] 公司深度报告 [Table_StockAndRank] 医脉通（2192.HK） 投资评级 买入 上次评级 [Table_Chart] 资料来源： ifind ，信达证券研发中心 [Table_BaseData] 公司主要数据 | 收盘价（港元） | 14.65 | | --- | --- | | 52 周内股价波动区间 | 6.71-17.18 | | (港元) | | | 最近一月涨跌幅(％) | -2.33 | | 总股本(亿股) | 7.34 | | 流通 H 股比例(％) | 100 ...

Core Viewpoint - The company reported a significant increase in revenue and profit for the six months ending June 30, 2025, indicating strong financial performance and growth potential in the market [1] Financial Performance - Revenue reached approximately 312 million RMB, representing a year-on-year growth of 28.2% [1] - Profit attributable to the owners of the parent company was approximately 155 million RMB, showing a year-on-year increase of 5.9% [1] - Adjusted net profit under non-Hong Kong Financial Reporting Standards was about 167 million RMB, reflecting a year-on-year growth of 6.9% [1] - Basic earnings per share were reported at 21.2 cents [1] - The company declared an interim dividend of 11.66 cents per ordinary share [1]